[1] Cascium S, Craziano F, Catalana G. Chemotherapy for ad-vanced pancreatic cancer: It may no longer be ignored [J]. Ann Oncol,1999,10(1):105.
[2] Saif MW.A new developments in the treatment of pancreatic cancer[J]. Highlights from the “ 44th ASCO Annual Meet-ing”.Chicago,IL,USA.May 30-June 3,2008.JOP 2008, 9:391-397.
[3] Tanaka M,Javle M,Dong X, et al.Gemcitabine metabolic and transporter gene polymorphisms are associated with drug toxicity and efficacy in patients locally pancreatic cancer [J]. Cancer,2010,116(22):5325-5335.
[4] Vervenne W,Bennouna J,Humblet Y,et al.A randomized, double blind,placebo controlled multicenter phase III trial to evaluate the efficacy and safety of adding bevacizumab to erlo-tinib and gemcitabine in patients with metastatic pancreatic cancer[J].J Clin Oncol,2008,26(suppl):4507.
[5] Okino H, Maeyama R, Manabe T. Trans-tissue, sustained release of gemcitabine from photo cured gelatin gel inhibits the growth of heterotopic human pancreatic tumor in nude mice[J].Cli Cancer Res.2003,9 (15):5786-5793.
[6] Rosemurgy AS,Serafini FM. New directions in systemic therapy of pancreatic cancer [J]. Cancer Control, 2000,7 (5):437-51.
[7] Howell SB.Clinical applications of a novel sustained-release injectable drug delivery system: DepoFoamTM technology[J].Cancer J 2001,7(3):219-227.
[8] Kim YJ, Kim SW. Controlled drug delivery from injectable biodegradable triblock copolymer [M]. Washington:Ameri-can Chemical Society,2003:300-311.
[9] Jeong B,Bae YH.Biodegradable block copolymers as inject-able drug-delivery systems [J]. Nature,1997, 388 (6645): 860-862.
[10] 杨 梅,李井泉,汤致强。PLGA 吉西他滨缓释微球在荷胰腺 癌裸鼠体内的药动学研究[J].中国药学杂志,2010,45 (4): 295-299.